Bio-Thera Follows Hikma Deal With Sandoz Bevacizumab Alliance
Hikma Ustekinumab Deal Signed In Late August; Sandoz Oncology Pipeline Boosted
Sandoz has plugged another gap in its off-patent oncology pipeline, from which the company has rolled-out four marketed oncology biosimilars, by bringing in Bio-Thera Solutions’ BAT1706 proposed biosimilar to Avastin, including in the US and Europe.
